NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia to Showcase MammaPrint and BluePrint Utility in Guiding Anthracycline Therapy at the 2025 San Antonio Breast Cancer Symposium
Four additional poster presentations from the ongoing real-world FLEX Study highlight the value of real-world data in personalizing chemotherapy decisions and improving outcomes in early-stage breast cancer IRVINE, Calif., and AMSTERDAM — November 25, Read More
Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – August 12, 2025 – Agendia, Inc., a leader in innovative genomic testing for breast cancer, today announced the publication of new findings in JNCI Cancer Spectrum validating Read More
Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting
FLEX Study Highlights Clinical Utility of MammaPrint® and BluePrint® in Diverse Patient Populations Across Breast Cancer Subtypes IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 27, 2025 – Agendia®, Inc., a leader in precision Read More
Newsroom
News, Stories & Breast Cancer Blog
Understanding Risk of Recurrence in Breast Cancer
Hearing the words “You have breast cancer” can change everything in an instant. It’s an overwhelming moment—filled with uncertainty, hope, and countless decisions about surgery, chemotherapy, radiation, and recovery. Yet, even after treatment ends, a single, Read More
For Breast Cancer Patients, Genomic Tests Enable Personalized Treatment Options
Breast cancer comes with many variables. A pair of powerful genomic tests can help women and their care teams make personalized care decisions. For the more than 300,000 women diagnosed with breast cancer Read More
Early Breast Cancer: Personalizing Chemotherapy Decisions
Using real-world data from the FLEX registry, MammaPrint, a 70-gene signature for risk of distant recurrence, was found to be predictive of chemotherapy benefit and distant recurrence-free interval prognosis in early-stage breast cancer. Read More
SABCS25: Agendia’s Genomic Testing Guides Breast Cancer Care
Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer. Agendia, a precision oncology company focused on early-stage breast Read More
Leveraging Real-World Evidence To Personalize Adjuvant Therapy in HR+/HER2- Early Breast Cancer
Publication: JNCI Cancer Spectrum, 2025, 9(5), pkaf092 Authors: Yael Bar, MD, PhD , Steven J. Isakoff , MD, PhD , Seth A. Wander , MD, PhD Title: Leveraging real-world evidence to personalize adjuvant therapy Read More
Mapping Your Path: How Genomic Testing Can Personalize Your Breast Cancer Treatment Plan
Genomic testing can help personalize your breast cancer treatment plan by helping map a path ahead. When navigating a breast cancer diagnosis, it can feel like approaching one fork in the road after another. Read More
Test May Predict Breast Cancer Recurrence Risk, Chemotherapy Benefit
For patients with HR+, HER2- early breast cancer, MammaPrint may predict distant recurrence-free interval prognosis and chemotherapy benefit.Key TakeawaysMammaPrint effectively predicts chemotherapy benefit and distant recurrence-free interval in HR+HER2- early breast cancer.High-risk patients benefit significantly Read More
